Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study

26 week extension study of the LixiLan-G trial (total 52 weeks treatment) found that glycaemic control achieved at 26 weeks with a once-daily titratable fixed-ratio combination of insulin glargine and lixisenatide was maintained at week 52 (HbA1c 6.7% at both 26 and 52 weeks).

Source:

Diabetes Care